SEC Tracker
Get the app
SLN · XBRL financial data

Silence Therapeutics financial statements, every quarter

The same tables from 11 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (SLN's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers——year onlyyear only25,305*14222415934*4220
Cost of goods and services sold——year onlyyear only2,038*54856412*110
Gross profit——year onlyyear only23,267*881399522*4110
Research and development——year onlyyear only22,077*20,81317,64720,5448,749*9,1229,148
General and administrative——year onlyyear only5,542*7,6845,1315,7953,734*7,0264,717
Operating income (loss)——year onlyyear only(4,352)*(28,409)(23,963)(26,244)(12,461)*(15,737)(13,865)
Income tax expense (benefit)——year onlyyear only324*01010*01
Net income (loss)——year onlyyear only12,302*(28,530)(27,354)(20,958)(11,770)*(14,957)(12,268)
Earnings per share, basic USD per share————0.09*(0.20)(0.19)(0.15)(0.08)*(0.11)(0.09)
Earnings per share, diluted USD per share————0.09*(0.20)(0.19)(0.15)(0.08)*(0.11)(0.09)
Weighted average shares, basic thousands of shares————141,662*141,679141,696141,702141,702*141,703141,710
Weighted average shares, diluted thousands of shares————141,662*141,679141,696141,702141,702*141,703141,710
Revenue thousands of GBPyear only——————————
Cost of sales thousands of GBPyear onlyyear onlyyear onlyyear only———————
Gross profit thousands of GBPyear onlyyear onlyyear onlyyear only———————
Research and development thousands of GBPyear onlyyear onlyyear onlyyear only———————
Operating profit (loss) thousands of GBPyear onlyyear onlyyear onlyyear only———————
Profit (loss) thousands of GBPyear onlyyear onlyyear onlyyear only———————

Balance sheet

CSV

Fiscal quarters (SLN's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents———68,789121,33064,88641,73982,03111,2775,65772,054
Short-term investments————26,00471,64872,41620,16173,83764,4210
Accounts receivable———29097241852800—
Total current assets———103,151187,366169,790148,553133,632118,658102,85294,281
Property and equipment, net———1,9381,8181,6931,7751,6551,5811,3961,325
Right-of-use asset———37015710758192167142117
Goodwill——9,6839,9819,3929,78410,61710,61210,62110,35810,325
Total assets———119,448202,635185,298165,233146,790131,442115,123106,412
Total current liabilities———22,33616,82219,26414,76817,37913,61310,46012,714
Lease liability, non-current———1180——9771439
Total liabilities———97,45568,61272,55571,07872,72769,13865,72167,941
Accumulated deficit———(431,894)(474,044)(502,536)(529,844)(550,802)(562,572)(577,526)(589,632)
Total stockholders' equity—12,37427,22121,993134,023112,74394,15574,06362,30449,40238,471
Total liabilities and equity———119,448202,635185,298165,233146,790131,442115,123106,412
Common shares outstanding (cover page) thousands of shares83,30689,785107,808118,847141,674141,691141,702141,702141,702141,704141,740
Cash and cash equivalents thousands of GBP27,44973,53754,81654,031———————
Total current assets thousands of GBP76,39986,33396,68681,021———————
Total current liabilities thousands of GBP25,57515,16721,94317,769———————
Total equity thousands of GBP9,0598,52622,07217,050———————

Cash flows

CSV

Fiscal quarters (SLN's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)——year onlyyear only12,302*(28,530)(27,354)(20,958)(11,770)*(14,957)(12,268)
Stock-based compensation——year onlyyear only3,981*3,5402,085*2,535*(86)*2,4471,308*
Net cash from operating activities——year onlyyear only(27,481)*(12,309)(21,784)*(10,891)*(17,287)*(15,603)1,518*
Purchases of property and equipment——year onlyyear only62*448*3*0*00*
Net cash from investing activities——year onlyyear only66,125*(44,381)(1,562)*51,289*(53,338)*10,00064,940*
Proceeds from issuing common stock——year onlyyear only(98)*141*0*0*02*
Net cash from financing activities——year onlyyear only(98)*141*0*0*02*
Net cash from operating activities thousands of GBPyear onlyyear onlyyear onlyyear only———————
Net cash from investing activities thousands of GBPyear onlyyear onlyyear onlyyear only———————
Net cash from financing activities thousands of GBPyear onlyyear onlyyear onlyyear only———————

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Silence Therapeutics72,05401,518*141.7M— 10-QJun 30, 2026
Cardiff Oncology9,197104(11,765)*77.8M2.9 quarters 10-QJun 30, 2026
Tvardi Therapeutics15,765not reported(9,228)*13.3M1.7 quarters 10-QJun 30, 2026
Rezolute10,615not reported(13,146)*96.7M8.2 quarters 10-KJun 30, 2026
Natures Sunshine Products82,503116,985835*17.6M— 10-QJun 30, 2026
Rocket Pharmaceuticals224,5070(39,613)*109.8M7.2 quarters 10-QJun 30, 2026
Perspective Therapeutics48,488not reported(20,650)*114.2M11.5 quarters 10-QJun 30, 2026
Esperion Therapeutics156,15880,104(27,722)257.4M5.6 quarters 10-QMar 31, 2026
Palvella Therapeutics187,803not reported(12,845)*14.4M19.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.